Genmab to Hold R&D Update on Company's Progress in 2015

Media Release

- **Four daratumumab presentations by Key Opinion Leaders to discuss data presented at the 2015 ASH meeting**
- **HuMax-TF-ADC presentation by Key Opinion Leader**
- **Discussion of Genmab's 2015 progress with proprietary technologies and pipeline products & company goals for 2016**
- **Live Webcast December 8**

Copenhagen, Denmark; December 1, 2015 – Genmab A/S (Nasdaq Copenhagen: GEN) will hold its annual R&D Update focused on the company's latest developments in antibody innovation on December 8, 2015 from 8:00 PM to 10:00 PM CET. The update will include presentations by key opinion leaders describing data from studies of daratumumab presented at the 57th Annual Meeting of the American Society of Hematology (ASH) as well as information on Genmab's pipeline product HuMax-TF-ADC. Genmab will also discuss the company's pre-clinical pipeline, the proprietary DuoBody® and HexaBody® technologies and will present its 2016 Key Goals.

The following cancer experts and senior Genmab staff will attend the event:

Daratumumab Key Opinion Leaders:

- Professor Thierry Facon, Professor of Hematology, Head of the Department of Hematology, Lille University Hospital, Lille, France
- Professor Maria Victoria Mateos, Associate Professor of Medicine, University Hospital of Salamanca, Salamanca, Spain
- Professor Torben Plesner, Department of Hematology, Vejle Hospital, Vejle, Denmark
- Dr. Peter Voorhees, M.D., Associate Professor, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, US

HuMax-TF-ADC Key Opinion Leader:

- Professor Johann de Bono, Director of the Drug Development Unit & Head of Prostate Cancer Targeted Therapy Group, Professor of Experimental Cancer Medicine & Honorary Consultant in Medical Oncology, The Institute of Cancer Research, Surrey, UK

Genmab:

- Dr. Jan van de Winkel, President and CEO, Genmab
- David Eatwell, Executive Vice President and CFO, Genmab

ASH abstracts to be discussed during the event include:

- Management of Infusion-related Reactions Following Daratumumab Monotherapy in Patients with ≥3 Lines of Prior Therapy or Double Refractory Multiple Myeloma (MM): 54767414MMY2002 (Sirius)
- Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
- Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results from a Phase 1/2 Study (GEN503)
- Open-label, Multicenter Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with ≥2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma (MM)

Genmab to Hold R&D Update on Company's Progress in 2015

The R&D Update is taking place at the Hyatt Regency Orlando in Orlando, Florida. Those wishing to attend in person should email c.hahner@genmab.com

The event can be attended via webcast. To view this webcast visit: http://edge.media-server.com/m/p/7o76r9qo. Webcast viewers may submit questions during the Q&A portion of the live webcast via the webcast player. An archive of the webcast will be available on Genmab's website. The webcast will be conducted in English.

This meeting is not an official program of the ASH Annual Meeting.

About Genmab
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX™ (daratumumab) for the treatment of heavily pretreated or double refractory multiple myeloma. Daratumumab is in clinical development for additional multiple myeloma indications and for non-Hodgkin's lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Media Release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements in relation to actual results, unless required by law.